Recent Investment Analysts’ Ratings Updates for Palisade Bio (PALI)

Palisade Bio (NASDAQ: PALI) recently received a number of ratings updates from brokerages and research firms:

• 7/14/2026 – Palisade Bio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/13/2026 – Palisade Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/5/2026 – Palisade Bio was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/30/2026 – Palisade Bio was given a new $7.00 price target by Oppenheimer Holdings, Inc..
• 6/30/2026 – Palisade Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock.
• 6/29/2026 – Palisade Bio was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/27/2026 – Palisade Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/25/2026 – Palisade Bio was upgraded by LADENBURG THALM/SH SH to “strong-buy”.
• 6/9/2026 – Palisade Bio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insiders Place Their Bets

In related news, Director Robert Jr. Baltera purchased 25,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were purchased at an average cost of $1.96 per share, with a total value of $49,000.00. Following the transaction, the director directly owned 461,904 shares in the company, valued at $905,331.84. This trade represents a 5.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John David Finley sold 146,798 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the sale, the chief executive officer directly owned 217,555 shares in the company, valued at approximately $450,338.85. This represents a 40.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have acquired 125,000 shares of company stock worth $250,100. 0.07% of the stock is currently owned by company insiders.

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.